Addressing the Foe Behind Covid-19 Deaths: Acute Respiratory Distress Syndrome
Dr. Joe G.N. Garcia, also an Endowed professor of medicine at the University of Arizona College of Medicine – Tucson and also the CEO of Aqualung Therapeutics, an early-stage biotech firm working on developing immune-focused therapeutic antibodies for patients suffering from disorders characterized by acute and chronic lung and systemic inflammation joins eHealth Radio and the Health News and Respiratory Channels.
Listen to interview with host Eric Michaels and guest Dr. Joe G.N. Garcia discuss the following:
- You have devoted your career to lung health. Can you tell us about yourself Dr. Garcia?
- Can you describe Acute Respiratory Distress Syndrome (ARDS)? Who is at most risks?
- How does the Coronavirus make treating ARDS so challenging?
- Tell us about your new company, Aqualung Therapeutics. What is your approach towards addressing ARDS?
- Where do you now stand as far as research? When do you believe this treatment will be made available to patients and would it be in time for the next outbreak of COVID-19 or other pandemics?
Joe G. N. "Skip" Garcia, MD, a world-renowned pulmonary physician-scientist, an endowed professor of medicine at the University of Arizona College of Medicine – Tucson, who heads the Garcia Lab at the University of Arizona and an elected member of the Institute of Medicine of the National Academies. A noted health administrator, scholar and educator, Dr. Garcia also is a leading authority on the genetic basis of lung disease and the prevention and treatment of inflammatory lung injury.
Website: www.aqualungtherapeutics.com
